Researchers from Paris, France conducted the multicentre observational study MINOR-STROKE in which they included 721 patients with intravenous thrombolysis-treated minor strokes (NIH Stroke Scale/Score [NIHSS] â€5) with large vessel occlusion intended for intravenous thrombolysis alone, including those patients who eventually received thrombectomy because of END. END was defined as a â„4-point NIHSS increase within 24 hours after admission. Mean age of participants was 70 years, median NIHSS was 3. Occlusion was located in the internal carotid artery (ICA)-T/L in 3%, in the tandem cervical ICA+middle cerebral artery in 10%, in the proximal M1 in 7%, in the distal M1 in 21%, in the M2 in 54%, and in the basilar artery in 4%. The thrombus was visible in 85% of patients.
END occurred in 12% and was associated with poor outcome after 3 months. In a multivariable analysis, a more proximal occlusion site (P<0.001) and a longer thrombus (P=0.002) were independently associated with END. Rates of END according to occlusion type were the following:
- ICA-T/L, 55%;
- Tandem occlusion, 23%;
- Proximal M1 occlusion, 19%;
- Distal M1 occlusion, 13%;
- Distal M2 occlusion, 5%;
- Basilar artery occlusion, 27%.
In patients with a thrombus length of <6, 6-9, 9-12, and â„12 mm, respectively, END occurred in 5%, 7%, 15%, and 23%.
- Seners P, et al. Abstract O2036, EAN 2020.
Posted on
Previous Article
« Endovascular treatment in large vessel occlusion stroke patients treated with OAC Next Article
Extubation after thrombectomy: the sooner, the better »
« Endovascular treatment in large vessel occlusion stroke patients treated with OAC Next Article
Extubation after thrombectomy: the sooner, the better »
Table of Contents: EAN 2020
Featured articles
Alzheimer's Disease and Other Dementias
Non-Alzheimerâs disease pathophysiology in the elderly
Novel genetic association with resistance to ERC tau deposition
Diastolic dysfunction novel risk factor for cognitive impairment
Epilepsy
Avoidable epilepsy-related mortality remains high
How genetic testing can contribute to epilepsy management
Cenobamate effective in focal epilepsy
Sustained seizure reductions with cannabidiol for Lennox-Gastaut syndrome
Prevalence of autoantibodies in epilepsy almost 10%
Parkinson's Disease
White matter matters in Parkinsonâs disease
Sleep disorders mark PD progression
Directional DBS superior to omnidirectional DBS
Stroke
Benefits of statins to prevent stroke outweigh risks
Extubation after thrombectomy: the sooner, the better
Thrombus location and length predictors of early neurological deterioration
Endovascular treatment in large vessel occlusion stroke patients treated with OAC
Early edoxaban may be safe after cardioembolic stroke
Headache and Pain
Small fibre pathology as biomarker for fibromyalgia
Migraine as a cyclical functional disorder
Reassuring real-world safety profile of 3 CGRP inhibitors
Long-term cardiovascular safety of erenumab
Real-world data for erenumab in Germany
Eptinezumab in chronic migraine and medication-overuse headache
Fremanezumab tolerability in cardiovascular patients with migraine
Effects of galcanezumab on health-related quality of life
Multiple Sclerosis
Imaging to evaluate remyelination and neuroprotection
Serum NfL predicts long-term clinical outcomes in MS
Epstein-Barr virus-targeted T-cell immunotherapy for progressive MS
High NEDA rates after 2 years of ocrelizumab
Switching from natalizumab to moderate- versus high-efficacy DMT
Results of compounds in late stages of development
Alemtuzumab efficacy and safety data of over 9 years
Fampridine treatment results in routine clinical practice
Air pollution is a possible risk factor for MS
Neuromyelitis Optica Spectrum Disorder
Genetic association studies in NMOSD needed
Eculizumab in NMOSD: the PREVENT study
Long-term safety of satralizumab consistent with double-blind periods
Neuromuscular Disorders
Biomarkers predicting motor function in SMA
Sustained benefits of avalglucosidase alfa in late-onset Pompe disease
Efficacy and safety of rituximab in refractory MG corroborated
Related Articles
September 9, 2020
White matter matters in Parkinsonâs disease
September 10, 2020
Imaging to evaluate remyelination and neuroprotection
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com